IGBA, the International Generic and Biosimilar medicines Association, representing global manufacturers of generic and biosimilar medicines, announced today that Medicines UK has joined IGBA as a new Associate Member.
The International Generic and Biosimilar Medicines Association (IGBA), has appointed Ana Gaunt as its new Secretary General with immediate effect, following the decision of Susana Almeida to step down from the role to pursue other opportunities.
Sustainable and responsible financing—powered by multisectoral collaboration—is key to meet the needs of people living with or affected by NCDs, including reducing out-of-pocket costs and ensuring affordable access to NCD medicines, products, and services.
- Jim Keon of CGPA Takes Over as IGBA Chair (January 2026)
- Single Global Development of Generic and Biosimilar Medicines: a cornerstone of Patient Access (December 2025)
- The IGBA CEO Advisory Committee: Patient Access, Industry Value, and Global Cooperation in a Reshaping World (December 2025)
- WHO Director General Reaffirms the Critical Role of Quality-Assured Generic and Biosimilar Medicines at WHO Global Forum for Public Procurement of Health Products (November 2025)
